| scholarly article | Q13442814 |
| P50 | author | James E. Crowe, Jr. | Q37366747 |
| P2093 | author name string | Robert E Johnston | |
| Sujin Lee | |||
| Bryan E Shepherd | |||
| Vasiliy V Polosukhin | |||
| Thomas J Utley | |||
| Martha L Collier | |||
| Nancy L Davis | |||
| Hoyin Mok | |||
| P2860 | cites work | Recombinant vaccinia immunization in the presence of passively administered antibody | Q72809092 |
| Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis | Q24796792 | ||
| Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters | Q27488907 | ||
| Sindbis virus translation is inhibited by a PKR/RNase L-independent effector induced by alpha/beta interferon priming of dendritic cells | Q33718551 | ||
| Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge | Q33783066 | ||
| Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis | Q33796546 | ||
| Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge | Q33849224 | ||
| Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses | Q33850032 | ||
| Role of alpha/beta interferon in Venezuelan equine encephalitis virus pathogenesis: effect of an attenuating mutation in the 5' untranslated region | Q33851223 | ||
| Humoral and cellular immune responses of seronegative children vaccinated with a cold-adapted influenza A/HK/123/77 (H1N1) recombinant virus | Q33900747 | ||
| Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine | Q34206177 | ||
| Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector | Q34302198 | ||
| Gamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment | Q34347904 | ||
| Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles | Q34357038 | ||
| Mucosal and systemic adjuvant activity of alphavirus replicon particles. | Q34410789 | ||
| Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. | Q34479873 | ||
| Alphavirus replicon particles as candidate HIV vaccines | Q34743830 | ||
| Exposure of neonates to respiratory syncytial virus is critical in determining subsequent airway response in adults | Q35023114 | ||
| Intranasal immunization of guinea pigs with an immunodominant foot-and-mouth disease virus peptide conjugate induces mucosal and humoral antibodies and protection against challenge | Q35149731 | ||
| Viral infections, atopy, and asthma: is there a causal relationship? | Q35615835 | ||
| Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern | Q35859950 | ||
| A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. | Q35861566 | ||
| Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus | Q35872191 | ||
| Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus | Q36355326 | ||
| Distinct types of lung disease caused by functional subsets of antiviral T cells | Q36362647 | ||
| Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus | Q36401291 | ||
| The cytolytic activity of pulmonary CD8+ lymphocytes, induced by infection with a vaccinia virus recombinant expressing the M2 protein of respiratory syncytial virus (RSV), correlates with resistance to RSV infection in mice. | Q36641979 | ||
| Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived | Q36683018 | ||
| Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by ant | Q36691093 | ||
| Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus | Q36858777 | ||
| Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses | Q36873249 | ||
| Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine | Q37208256 | ||
| Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity | Q37401975 | ||
| The transmembrane domain of the respiratory syncytial virus F protein is an orientation-independent apical plasma membrane sorting sequence | Q40373839 | ||
| A novel viral system for generating antigen-specific T cells | Q40395143 | ||
| Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming | Q40581836 | ||
| Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses | Q40749115 | ||
| Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo | Q40771213 | ||
| Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV. | Q40883566 | ||
| An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine | Q40940832 | ||
| Respiratory syncytial virus G glycoprotein expressed using the Semliki Forest virus replicon is biologically active | Q40967253 | ||
| Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo | Q41071177 | ||
| Mucosal immunity induced by parenteral immunization with a live attenuated Venezuelan equine encephalitis virus vaccine candidate | Q41127255 | ||
| Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization | Q41343225 | ||
| A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees | Q41458369 | ||
| Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis | Q41463572 | ||
| Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice | Q44022532 | ||
| Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized wit | Q44050942 | ||
| Evaluation of FIV protein-expressing VEE-replicon vaccine vectors in cats | Q44856355 | ||
| A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge | Q45213829 | ||
| Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. | Q45436993 | ||
| Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants | Q45504141 | ||
| Real-time PCR to improve the diagnosis of respiratory syncytial virus infection | Q45721811 | ||
| Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV. | Q45722558 | ||
| Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus | Q45731033 | ||
| Immune protection against staphylococcal enterotoxin-induced toxic shock by vaccination with a Venezuelan equine encephalitis virus replicon | Q45733054 | ||
| The role of IFN in respiratory syncytial virus pathogenesis | Q45733409 | ||
| Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. | Q45734910 | ||
| Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses | Q45739430 | ||
| Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. | Q45746795 | ||
| Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment | Q45763190 | ||
| Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene | Q45764676 | ||
| Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates | Q45771373 | ||
| Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3. | Q45774616 | ||
| A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. | Q45776569 | ||
| Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit | Q45780126 | ||
| Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine | Q45781115 | ||
| Systemic immunoprophylaxis of nasal respiratory syncytial virus infection in cotton rats | Q45784255 | ||
| Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse | Q45785790 | ||
| A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes | Q45785799 | ||
| Passively administered antibody suppresses the induction of measles virus antibodies by vaccinia-measles recombinant viruses | Q45787814 | ||
| Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. | Q45828600 | ||
| Comparison of lung histopathology and bronchoalveolar lavage cytology in mice and cotton rats infected with respiratory syncytial virus | Q45852446 | ||
| Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee | Q45868590 | ||
| Evaluation of Venezuelan Equine Encephalitis (VEE) replicon-based Outer surface protein A (OspA) vaccines in a tick challenge mouse model of Lyme disease. | Q51834480 | ||
| A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines | Q56689869 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virology | Q7215 |
| equine encephalitis | Q2083677 | ||
| Venezuelan equine encephalitis virus | Q473462 | ||
| Venezuelan equine encephalitis | Q18558169 | ||
| P304 | page(s) | 13710-13722 | |
| P577 | publication date | 2007-10-10 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats | |
| P478 | volume | 81 |
| Q33769306 | A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles |
| Q38130514 | Advances in and the potential of vaccines for respiratory syncytial virus |
| Q36949797 | An alphavirus replicon-based human metapneumovirus vaccine is immunogenic and protective in mice and cotton rats |
| Q35595950 | An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children |
| Q36106575 | Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice |
| Q34457791 | Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins |
| Q42138587 | Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus |
| Q34504791 | Biological challenges and technological opportunities for respiratory syncytial virus vaccine development |
| Q28752489 | Comparison of the immune responses induced by chimeric alphavirus-vectored and formalin-inactivated alum-precipitated measles vaccines in mice |
| Q38919640 | CpG in Combination with an Inhibitor of Notch Signaling Suppresses Formalin-Inactivated Respiratory Syncytial Virus-Enhanced Airway Hyperresponsiveness and Inflammation by Inhibiting Th17 Memory Responses and Promoting Tissue-Resident Memory Cells i |
| Q33972018 | Enhancement of protein expression by alphavirus replicons by designing self-replicating subgenomic RNAs |
| Q41557807 | Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350. |
| Q34440116 | Ginseng diminishes lung disease in mice immunized with formalin-inactivated respiratory syncytial virus after challenge by modulating host immune responses |
| Q36515541 | Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates |
| Q37263840 | Immunogenicity of RSV F DNA Vaccine in BALB/c Mice. |
| Q37617698 | Immunomodulatory activity of red ginseng against influenza A virus infection |
| Q27021304 | Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design |
| Q36458651 | Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particles |
| Q35868095 | Interleukin-27 inhibits vaccine-enhanced pulmonary disease following respiratory syncytial virus infection by regulating cellular memory responses |
| Q36086236 | Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity |
| Q37215818 | Lactobacillus plantarum DK119 as a probiotic confers protection against influenza virus by modulating innate immunity |
| Q37649439 | Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease |
| Q34059404 | Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory |
| Q33837530 | Mucosal vaccines against respiratory syncytial virus |
| Q40021844 | NADPH oxidase limits lipopolysaccharide-induced lung inflammation and injury in mice through reduction-oxidation regulation of NF-κB activity |
| Q36266896 | Need for a safe vaccine against respiratory syncytial virus infection. |
| Q39780308 | Newcastle disease virus-like particles as a platform for the development of vaccines for human and agricultural pathogens |
| Q33558475 | Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology |
| Q56894869 | Progress in respiratory virus vaccine development |
| Q36739674 | Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin |
| Q37106159 | Pulmonary V gamma 4+ gamma delta T cells have proinflammatory and antiviral effects in viral lung disease |
| Q30380898 | Recombinant vectors as influenza vaccines. |
| Q56893551 | Respiratory syncytial virus vaccine development |
| Q84854616 | Respiratory syncytial virus vaccine development |
| Q38079432 | Respiratory syncytial virus: current progress in vaccine development |
| Q38255634 | Self-replicating alphavirus RNA vaccines. |
| Q37118707 | Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses |
| Q40065136 | Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles |
| Q37328584 | Targeting RSV with vaccines and small molecule drugs |
| Q38068469 | The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development. |
| Q37350360 | Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses |
| Q41812230 | Viral vectors for vaccine applications |
| Q38059059 | Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development |
| Q35188476 | Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice |
| Q64098587 | Will Attention by Vaccine Developers to the Host's Nuclear Hormone Levels and Immunocompetence Improve Vaccine Success? |
Search more.